Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MIRABEGRON EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for MIRABEGRON EXTENDED-RELEASE TABLETS. MIRABEGRON extended-release tablets, for oral use Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
Mirabegron Monotherapy Mirabegron is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Mirabegron Mirabegron is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.
- generic_name
- mirabegron
- product_names
- Mirabegron
- ndc
- 69238-2860, 69238-2860-1, 69238-2860-2, 69238-2861, 69238-2861-1, 69238-2861-2
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en